-
Product Insights
Emphysema – Drugs In Development, 2023
Global Markets Direct’s, ‘Emphysema - Drugs In Development, 2023’, provides an overview of the Emphysema pipeline landscape. The report provides comprehensive information on the therapeutics under development for Emphysema, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Acute Spinal Cord Injury – Drugs In Development, 2023
Global Markets Direct’s, ‘Acute Spinal Cord Injury - Drugs In Development, 2023’, provides an overview of the Acute Spinal Cord Injury pipeline landscape. The report provides comprehensive information on the therapeutics under development for Acute Spinal Cord Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Critical Limb Ischemia – Drugs In Development, 2023
Global Markets Direct’s, ‘Critical Limb Ischemia - Drugs In Development, 2023’, provides an overview of the Critical Limb Ischemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Critical Limb Ischemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Spinal Cord Injury – Drugs In Development, 2023
Global Markets Direct’s, ‘Spinal Cord Injury - Drugs In Development, 2023’, provides an overview of the Spinal Cord Injury pipeline landscape. The report provides comprehensive information on the therapeutics under development for Spinal Cord Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TED-N in Paralysis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TED-N in Paralysis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.TED-N in Paralysis Drug Details:Stem cell therapy is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cytisinicline in Smoking Cessation
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cytisinicline in Smoking Cessation report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Cytisinicline in Smoking CessationDrug Details:Cytisinicline (Tabex) is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TED-N in Acute Spinal Cord Injury
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TED-N in Acute Spinal Cord Injury report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.TED-N in Acute Spinal Cord InjuryDrug Details:Stem cell therapy is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – JBI-802 in Neuroendocrine Tumors
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - JBI-802 in Neuroendocrine Tumors report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.JBI-802 in Neuroendocrine Tumors Drug Details: JBI-802 is under development for the treatment...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Cellular Immunotherapy for Colorectal Cancer and Gastric Cancer
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry Cellular Immunotherapy for Colorectal Cancer and Gastric Cancer Drug Details Cellular immunotherapy is under...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Stem Cell Therapy for Critical Limb Ischemia
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry Stem Cell Therapy for Critical Limb Ischemia Drug Details Stem cell therapy is under...